MYCOF (Noveris Health Sciences) Piotroski F-Score: 4 (As of Jun. 27, 2026) — 33% Above Median


MYCOF Noveris Health Sciences Inc MYCOF
23 GF Score
Price $2.00
GF Value $0.52
Valuation Significantly Overvalued
View Full Analysis

What is Noveris Health Sciences Piotroski F-Score?

Noveris Health Sciences MYCOF 23 Piotroski F-Score is 4 as of Jun. 27, 2026, which is 33% above its 10-year median of 3.00. GuruFocus rates MYCOF with a GF Score™ of 23/100 and a GF Value™ of $0.52 (Significantly Overvalued). Among 981 Drug Manufacturers companies, Noveris Health Sciences ranks worse than 61.06% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Noveris Health Sciences has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Noveris Health Sciences's Piotroski F-Score or its related term are showing as below:

MYCOF' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 3   Max: 6
Current: 4

During the past 13 years, the highest Piotroski F-Score of Noveris Health Sciences was 6. The lowest was 1. And the median was 3.

Noveris Health Sciences  (OTCPK:MYCOF) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Noveris Health Sciences Piotroski F-Score Related Terms


Noveris Health Sciences Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Noveris Health Sciences's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Noveris Health Sciences Piotroski F-Score Chart

Noveris Health Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.00 2.00 2.00 2.00 3.00

Noveris Health Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.00 3.00 4.00 3.00 4.00

MYCOF vs ZTS: Piotroski F-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Noveris Health Sciences's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Noveris Health Sciences Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Noveris Health Sciences's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Noveris Health Sciences's Piotroski F-Score falls into.


MYCOF
23GF Score
Noveris Health Sciences Inc MYCOF
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was -0.01 + 0.053 + 2.29 + -1.179 = $1.15 Mil.
Cash Flow from Operations was -0.007 + 0.034 + -0.027 + -0.207 = $-0.21 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(0.007 + 0 + 0.034 + 0.007 + 1.496) / 5 = $0.386 Mil.
Total Assets at the begining of this year (Mar25) was $0.01 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Current Assets was $1.50 Mil.
Total Current Liabilities was $3.14 Mil.
Net Income was -1.947 + -1.47 + 1.755 + -0.208 = $-1.87 Mil.

Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(0.157 + 0.116 + 0.131 + 0.036 + 0.007) / 5 = $0.0894 Mil.
Total Assets at the begining of last year (Mar24) was $0.16 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Current Assets was $0.01 Mil.
Total Current Liabilities was $10.61 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Noveris Health Sciences's current Net Income (TTM) was 1.15. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Noveris Health Sciences's current Cash Flow from Operations (TTM) was -0.21. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=1.154/0.007
=164.85714286

ROA (Last Year)=Net Income/Total Assets (Mar24)
=-1.87/0.157
=-11.91082803

Noveris Health Sciences's return on assets of this year was 164.85714286. Noveris Health Sciences's return on assets of last year was -11.91082803. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Noveris Health Sciences's current Net Income (TTM) was 1.15. Noveris Health Sciences's current Cash Flow from Operations (TTM) was -0.21. ==> -0.21 <= 1.15 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=0/0.386
=0

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=0/0.0894
=0

Noveris Health Sciences's gearing of this year was 0. Noveris Health Sciences's gearing of last year was 0. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=1.496/3.139
=0.4765849

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=0.007/10.609
=0.00065982

Noveris Health Sciences's current ratio of this year was 0.4765849. Noveris Health Sciences's current ratio of last year was 0.00065982. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Noveris Health Sciences's number of shares in issue this year was 15.872. Noveris Health Sciences's number of shares in issue last year was 1.235. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0/0
=

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0/0
=

Noveris Health Sciences's gross margin of this year was . Noveris Health Sciences's gross margin of last year was . ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=0/0.007
=0

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=0/0.157
=0

Noveris Health Sciences's asset turnover of this year was 0. Noveris Health Sciences's asset turnover of last year was 0. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+0+1+0+1+1+0+0+0
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Noveris Health Sciences has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 4 mean?
Noveris Health Sciences (MYCOF) has a Piotroski F-Score of 4 as of Jun. 27, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Noveris Health Sciences and its competitors. This is 33% above median its historical median of 3.00. Over the past decade, Noveris Health Sciences' Piotroski F-Score has ranged from 1.00 to 6.00. According to the industry distribution chart, Noveris Health Sciences ranks #599 out of 981 companies in the Drug Manufacturers industry, placing it in the top 61.1%.
Is Noveris Health Sciences' Piotroski F-Score too high?
Noveris Health Sciences' current Piotroski F-Score of 4 is 33% above median its 10-year median of 3.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 6.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Noveris Health Sciences' value of 4 is 20% below this industry median. Based on the distribution chart, Noveris Health Sciences ranks #599 out of 981 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Noveris Health Sciences has a GF Score™ of 23/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Noveris Health Sciences' Piotroski F-Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Noveris Health Sciences ranks #599 out of 981 companies for Piotroski F-Score. This places Noveris Health Sciences in the lower half of its industry. The industry median Piotroski F-Score is 5.00. Noveris Health Sciences' value of 4 is 20% below this benchmark. Historically, Noveris Health Sciences' own Piotroski F-Score has ranged from 1.00 to 6.00 over the past decade. While the company's 10-year median is 3.00 vs. the industry median of 5.00, Noveris Health Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 981 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Noveris Health Sciences's current Piotroski F-Score of 4 is 20% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Noveris Health Sciences and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Noveris Health Sciences's current Piotroski F-Score is 4, which is 33% above median its own 10-year median of 3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Noveris Health Sciences stock overvalued right now?
Based on GuruFocus' analysis, Noveris Health Sciences (MYCOF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.52, compared to a current price of $2.00 — trading 284.6% above its estimated fair value. The current Piotroski F-Score is 4, which is 33% above median its 10-year median of 3.00 and 20% below the Drug Manufacturers industry median of 5.00. Noveris Health Sciences' overall GF Score™ is 23/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Noveris Health Sciences (MYCOF), the current Piotroski F-Score is 4 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Noveris Health Sciences (MYCOF) Overvalued in 2026?

Based on GuruFocus' analysis, Noveris Health Sciences stock appears to be overvalued. The current stock price of $2.00 is trading 284.6% above its estimated GF Value™ of $0.52. GuruFocus considers Noveris Health Sciences to be Significantly Overvalued.

Key valuation signals for MYCOF:

  • Piotroski F-Score: 4 (33% above median its 10-year median of 3.00)
  • GF Value™: $0.52 vs. price of $2.00 (284.6% above fair value)
  • GF Score™: 23/100
  • Industry Position: 20% below the Drug Manufacturers median (#599 of 981)

No single metric tells the full story. See the MYCOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Noveris Health Sciences Business Description

Other Exchanges 0NF1:GermanyNVRS:Canada
Address 1890 - 1075 West Georgia Street, Suite 810, Vancouver, BC, CAN, V6E 3C9
Noveris Health Sciences Inc is a biotech and life sciences company dedicated to developing and commercializing solutions for treating mental health problems and enhancing vitality. The company has a portfolio of patents it is seeking to commercialize, and is exploring opportunities in the stem cell industry. It is developing the next generation of medications and therapies to address mental health disorders such as nicotine addiction and post-traumatic stress disorder (PTSD).
23GF Score

Get the complete analysis for MYCOF

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.00
Price
$0.52
GF Value